Introduction/Overview
Natural products, as an important source of drug discovery, play an irreplaceable role in the history of human disease treatment. Among them, triterpenoids have always been a hot topic in medicinal chemistry and pharmacology research due to their structural diversity and wide range of biological activities. Virgaureagenin G, a pentacyclic triterpenoid compound isolated from traditional medicinal plants, has attracted much attention in recent years due to its significant activity and unique multi-target mechanism in the field of anti-tumor. Its CAS number is 22338-71-2, and its molecular skeleton is of the oleanane type. It is a glycoside of various bioactive saponins. Preliminary modern pharmacological research has revealed that Virgaureagenin G can exhibit inhibitory activity on various tumor cells through various pathways such as intervening in cell apoptosis, inhibiting tumor invasion and metastasis, and interfering with cell signaling. Its target proteins include MCL1, BCL2, STAT3, MMP2, TOP1, HIF1A, TOP2A, MAPK1, ESR1, CYP19A1, and other key proteins. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, molecular mechanism of action, pharmacological characteristics, and clinical application potential of Virgaureagenin G, in order to provide comprehensive scientific references for the in-depth research and future development of anti-tumor drugs of this compound.
Chemical structure and physicochemical properties
Mao Guo Yi Zhi Huang Huang saponin G belongs to the oleane type pentacyclic triterpenoid compounds. Its basic skeleton is composed of six isoprene units, forming five fused rings (A/B/C/D/E rings), with a typical pentacyclic triterpenoid stereoconfiguration. Its molecular formula is C ∝₀ H ₄₈ O ₆, and its molecular weight is 504.7080. Structural analysis shows that there are usually multiple oxygen-containing functional groups attached to its parent nucleus, such as hydroxyl and carboxyl groups, which are crucial for its physicochemical properties and biological activity.
From the analysis of parameters related to drug formation, the lipid water partition coefficient (LogP) of Virgaureagenin G is 3.7762, indicating that the compound has moderate lipophilicity, which is beneficial for its penetration of cell membranes but may also affect its water solubility. Its topological polar surface area (TPSA) is 118.2200 Å ², reflecting the presence of multiple hydrogen bond donor and acceptor sites in the structure. The water solubility parameter shows a low solubility (0.0471 mg/mL), which may be a potential limiting factor for its oral bioavailability. In terms of absorption and distribution, the predictive model shows that its ability to penetrate the blood-brain barrier (BBB) is low, suggesting that it may be limited in the treatment of central nervous system related tumors, but it may also reduce the risk of central neurotoxicity. Preliminary safety assessment shows that the hERG inhibition risk is negative, indicating a low potential risk of arrhythmogenic cardiac toxicity; The Ames test result is 0.0, indicating that it has no direct genetic toxicity. These physicochemical and preliminary safety parameters provide important basis for subsequent chemical modifications and formulation development.
Plant sources and extraction methods
The main source of saponin G in the hairy fruit yellow flower is from plants of the Solidago genus in the Asteraceae family, especially the hairy fruit yellow flower (Solidago virgaurea L.) and its related species. This genus of plants is widely distributed worldwide and is commonly used in traditional medicine to treat inflammation, urinary system diseases, and wound healing. Virgaureagenin G is usually present in the aboveground parts of plants, especially in flowers and leaves, in the form of saponins (such as Virgaureasaponin G), and the glycoside portion is obtained by acid hydrolysis or enzymatic hydrolysis of the corresponding saponins.
The extraction and separation purification process follows the conventional process of natural product chemistry. Firstly, the dried plant material is crushed and subjected to reflux extraction or ultrasound assisted extraction using polar solvents such as methanol, ethanol, or aqueous ethanol to obtain a crude extract rich in saponins. Subsequently, the crude extract was subjected to macroporous adsorption resin column chromatography, and gradient elution was performed using ethanol water solutions of different concentrations to preliminarily enrich the saponin components. The obtained saponin components are further subjected to acid hydrolysis (such as heating with dilute solutions of hydrochloric acid or sulfuric acid) to break the sugar chains and release the glycoside Virgaureagenin G. After hydrolysis, the mixture is neutralized and extracted (usually with ethyl acetate or chloroform) to obtain crude aglycones. The final purification relies on various modern chromatographic techniques, including normal phase silica gel column chromatography (using chloroform methanol system gradient elution), reverse phase high performance liquid chromatography (RP-HPLC, commonly using C18 column with methanol water or acetonitrile water as mobile phase), and preparative thin-layer chromatography. The chemical structure can be confirmed by nuclear magnetic resonance (NMR), mass spectrometry (MS), and comparison with literature data. Optimizing the extraction solvent, hydrolysis conditions, and chromatographic separation parameters are key to improving the yield and purity of Virgaureagenin G.
Pharmacological activity research
A large number of in vitro and in vivo pharmacological studies have shown that the core biological activity of saponin G in the hairy fruit yellow flower is concentrated in the field of anti-tumor, and it exhibits broad-spectrum and significant inhibitory activity against various human tumor cell lines.
1. In vitro anti-tumor activity:
Virgaureagenin G can inhibit the proliferation of breast cancer (such as MCF-7, MDA-MB-231), liver cancer (HepG2), lung cancer (A549), colon cancer (HT-29, HCT-116), prostate cancer (PC-3), leukemia (HL-60) and other cancer cells, and its IC ≮ value is mostly in the micromolar level. The functional characteristics include inducing cell cycle arrest (commonly in G0/G1 phase or G2/M phase) and triggering cell apoptosis. Apoptosis induction is manifested by morphological changes in cells (chromatin agglutination, nuclear fragmentation), phosphatidylserine eversion (Annexin V positive), and activation of Caspase family proteases (such as Caspase-3, -8, -9).
2. In vivo anti-tumor activity:
In nude mice transplanted tumor models (such as human breast cancer and liver cancer transplanted tumor), intraperitoneal injection or intragastric administration of Virgaureagenin G can significantly inhibit the growth of tumor volume and tumor weight in a dose-dependent manner. Some studies have shown that its anti-tumor effect is comparable or slightly better than positive control drugs (such as 5-fluorouracil), and it does not cause significant toxicity to mouse body weight and major organs (heart, liver, spleen, lungs, kidneys) within a certain dose range, indicating that it has good in vivo anti-tumor activity and preliminary safety window.
3. Other potential activities:
In addition to its direct anti-tumor effect, based on its structural characteristics and preliminary research, Virgaureagenin G may also have anti-inflammatory and antioxidant activities. These auxiliary activities may indirectly enhance its anti-tumor effect by improving the tumor microenvironment, but further research is needed.
Mechanism of action and molecular targets
The anti-tumor effect of Virgaureagenin G is not achieved through a single pathway, but involves a complex multi-target regulatory network, mainly including inducing apoptosis, inhibiting invasion and metastasis, regulating signaling pathways, and affecting hormone metabolism.
1. Regulating apoptosis related proteins (targeting MCL1 and BCL2):
Virgaureagenin G can downregulate the expression of anti apoptotic proteins B cell lymphoma 2 (BCL2) and myeloid leukemia 1 (MCL1), while possibly upregulating the expression of pro apoptotic proteins such as BAX and BID, leading to increased mitochondrial outer membrane permeability, release of cytochrome C, and activation of Caspase-9 and Caspase-3, inducing endogenous apoptotic pathways. This is one of the core mechanisms by which it induces apoptosis in tumor cells.
2. Inhibit signal transduction and transcription activator 3 (STAT3):
STAT3 is an important oncogenic transcription factor, and sustained activation of STAT3 promotes tumor cell proliferation, survival, and immune escape. Virgaureagenin G has been shown to inhibit the phosphorylation (Tyr705 site) and nuclear translocation of STAT3, thereby downregulating the expression of downstream target genes (such as Cyclin D1, Bcl xL, and Survivors), inhibiting cell proliferation, and promoting apoptosis.
3. Inhibition of matrix metalloproteinases (targeting MMP2):
Tumor invasion and metastasis depend on the degradation of extracellular matrix. Virgaureagenin G can significantly inhibit the activity and expression of matrix metalloproteinase-2 (MMP2). MMP2 is a key enzyme for degrading type IV collagen (the main component of the basement membrane), and inhibition of its activity can effectively reduce the migration and invasion ability of tumor cells.
4. Impact on DNA topoisomerases (targeting TOP1, TOP2A):
DNA topoisomerases I (TOP1) and II α (TOP2A) are key enzymes that maintain the topological structure of DNA and are also targets of various chemotherapy drugs. Research has shown that Virgaureagenin G may cause irreparable damage during DNA replication and transcription by interfering with the catalytic functions of TOP1 and TOP2A, leading to DNA damage reactions and cell death.
5. Inhibit hypoxia inducible factor-1 alpha (HIF1A):
In the hypoxic microenvironment of tumors, the stability and activation of HIF1A promote angiogenesis and metabolic reprogramming. Virgaureagenin G can downregulate the level of HIF1 α protein, inhibit its transcriptional activity, thereby reducing the expression of angiogenic factors such as vascular endothelial growth factor (VEGF) and inhibiting tumor angiogenesis.
6. Regulating the mitogen activated protein kinase pathway (targeting MAPK1/ERK2):
The MAPK/ERK pathway regulates cell growth and differentiation. The regulatory effect of Virgaureagenin G on MAPK1 (i.e. ERK2) activity is cell type dependent, and may block abnormal proliferation signals by inhibiting its overactivation.
7. Intervention in estrogen related pathways (targeting ESR1, CYP19A1):
For estrogen receptor positive (ER+) breast cancer, Virgaureagenin G may have dual effects: on the one hand, it may act as a modulator of estrogen receptor alpha (ESR1), interfering with estrogen signal transduction; On the other hand, it may inhibit the activity of aromatase (CYP19A1), which is the rate limiting enzyme for the transformation of androgen into estrogen. Its inhibition can reduce the estrogen level in the body, thus inhibiting the growth of hormone dependent breast cancer.
In summary, Virgaureagenin G forms a synergistic anti-tumor network by simultaneously acting on multiple key targets and pathways, which helps overcome the resistance problem of single target drugs, but also poses challenges for fully elucidating its mechanism of action.
Evaluation of drug properties and pharmacokinetics
Although the saponin G from Magnolia officinalis has shown good anti-tumor potential in vitro and in vivo models, its pharmacological properties still need to be systematically evaluated.
1. Absorption, distribution, metabolism, and excretion (ADME) characteristics:
Based on its physicochemical properties (moderate LogP, low water solubility, high TPSA), it is predicted that the oral absorption of Virgaureagenin G may be moderate, but there are significant individual differences. Its low blood-brain barrier permeability limits its effect on brain tumors, but as mentioned earlier, it may also reduce central side effects. At present, there is very limited publicly available data on its systemic pharmacokinetic studies in vivo, such as bioavailability, plasma protein binding rate, tissue distribution, metabolic pathways, and excretion. Triterpenoids are usually prone to undergo phase I (such as oxidation and reduction) and phase II (such as glucuronidation and sulfation) metabolism in the liver, and the activity and toxicity of their metabolites need to be studied. The prototype drug and its metabolites may be mainly excreted through bile and feces, with some excreted through the kidneys.
2. Exploration of dosage form and administration route:
To improve its bioavailability, it may be necessary to develop novel drug delivery systems. For example, the use of nanotechnology (such as liposomes, polymer nanoparticles, solid lipid nanoparticles) to encapsulate Virgaureagenin G can improve its water solubility, enhance targeted accumulation at the tumor site (through enhanced permeation and retention effects or active targeting), and potentially achieve sustained release, thereby improving efficacy and reducing systemic toxicity. In addition, cyclodextrin inclusion, microemulsion, and self microemulsifying drug delivery systems are also potential directions for dosage form improvement.
3. Preliminary safety assessment:
The existing data suggests that there is no risk of hERG inhibition and Ames mutagenicity, which is a favorable factor for its early development. However, comprehensive preclinical safety evaluations (including acute toxicity, chronic toxicity, reproductive toxicity, immunotoxicity, etc.) have not been systematically reported. As a natural product, its potential organ toxicity (especially in the liver and kidneys) and interactions with other drugs require further investigation.
Clinical application prospects and prospects
As a natural lead compound with multiple targets for anti-tumor treatment, the application prospect of Maoguo Huanghua Saponin G is broad, but it also faces many challenges.
1. Direct development and combination therapy:
Virgaureagenin G itself can be extensively developed as a candidate drug. Given its multi-target nature, it may be effective against certain tumor types that are resistant to existing chemotherapy drugs. A more realistic strategy is to combine it with existing standard chemotherapy drugs (such as paclitaxel, cisplatin, 5-fluorouracil) or targeted drugs, enhance efficacy through synergistic effects of different mechanisms, reduce individual doses and toxic side effects, and overcome drug resistance.
2. Structural modification and optimization:
Reasonable structural modification using it as the mother nucleus is the key path to enhance drug efficacy. Pharmaceutical chemists can derivatize its carboxyl, hydroxyl, and other sites with the aim of: ① improving water solubility and oral bioavailability (such as preparing water-soluble prodrug salts or esters); ② Enhance selectivity and affinity for specific targets (computer-aided drug design based on target crystal structure); ③ Improve pharmacokinetic properties (such as metabolic stability); ④ Reduce potential toxicity. The synthesis of a series of derivatives and the study of structure-activity relationships are important directions for the future.
3. Development of new formulations:
As mentioned earlier, the development of targeted nano formulations, liposomes and other novel delivery systems is expected to solve the problems of low solubility and poor in vivo distribution, achieve tumor specific delivery, and maximize treatment index.
4. Expand the field of diseases:
In addition to anti-tumor effects, based on the common anti-inflammatory and immunomodulatory activities of triterpenoids, Virgaureagenin G is also worth exploring in the fields of autoimmune diseases, chronic inflammatory diseases, and other related areas.
The challenges faced mainly include: ① The establishment of large-scale, stable, and sustainable plant sources or fully synthetic/semi synthetic routes to meet subsequent development needs; ② Accurate analysis of complex multi-target mechanisms and determination of primary secondary relationships; ③ Obtaining comprehensive preclinical pharmacodynamic, pharmacokinetic, and toxicological research data; ④ Identify its optimal indications and potential biomarkers.
Conclusion
Mao Guo Yi Zhi Huang Huang saponin G is a natural product of pentacyclic triterpenoids with significant anti-tumor activity discovered from traditional medicinal plants. Its unique chemical structure endows it with multiple pharmacological effects by intervening in multiple key targets such as MCL1, BCL2, STAT3, MMP2, TOP1, HIF1A, TOP2A, MAPK1, ESR1, CYP19A1, etc., thereby inducing apoptosis, inhibiting proliferation, blocking invasion and metastasis, and regulating the tumor microenvironment. Despite challenges such as low water solubility and unclear pharmacokinetic properties in drug development, these challenges provide clear optimization directions for pharmaceutical chemistry, pharmacy, and pharmacology research. Through in-depth structural modification, rational dosage form design, and rigorous preclinical and clinical research, Virgaureagenin G is expected to be developed into a novel, efficient, multi-target anti-tumor drug or its lead compound, which not only provides new options for tumor treatment, but also further confirms the important value of finding innovative drugs from natural treasure trove. Future research should focus on the mapping of its mechanism of action, deep optimization of drug properties, and comprehensive evaluation for clinical translation.
